Want to see SI full AI Analyst Report?
SI Stock Chart & Stats
$20.64
$0.55(2.69%)
At close: 4:00 PM EDT
$20.64
$0.55(2.69%)
Day’s Range― - ―
52-Week Range$10.92 - $24.60
Previous Close$15.29
Volume51.57K
Average Volume (3M)114.33K
Market Cap
$393.48M
Enterprise Value$336.38
Total Cash (Recent Filing)$98.99M
Total Debt (Recent Filing)$14.85M
Price to Earnings (P/E)―
Beta-0.45
Next Earnings
Nov 17, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding20,818,956
10 Day Avg. Volume160,436
30 Day Avg. Volume114,330
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)2.10
Price to Sales (P/S)6.23
P/FCF Ratio-8.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$26.33Price Target Upside27.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.88
Revenue Forecast (FY)$68.42M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth And High Gross MarginsFast revenue expansion combined with consistently high gross margins indicates that the shoulder implant portfolio has attractive underlying unit economics. If maintained as adoption broadens, this combination can provide substantial gross profit to fund commercial investment and support eventual operating leverage.
Low Leverage And Expanding Capital BaseManageable leverage gives Shoulder Innovations more balance-sheet flexibility than a highly indebted growth company. The larger equity and asset base can support continued commercialization and reduce immediate debt pressure, although the benefit depends on improving operations so capital is not primarily consumed by losses.
Strengthened Commercial ExecutionA dedicated commercial leadership mandate focused on surgeon and partner relationships, hospitals, outpatient centers, and the innovation pipeline could improve execution as the company scales. Osborne’s cited orthopedic industry experience may help convert product differentiation into broader procedural adoption over coming quarters.
Bears Say
Deepening Operating And Net LossesThe company’s strong gross margin is not yet translating into viable earnings because operating expenses are growing faster than revenue. Persistently deepening operating and net losses reduce financial resilience and make future profitability dependent on significant cost discipline or continued external funding.
Accelerating Cash BurnNegative operating and free cash flow show that Shoulder Innovations has not yet demonstrated self-funding operations. Accelerating burn alongside larger losses increases the amount of capital needed to sustain commercialization, leaving the business more exposed to financing conditions over the next several quarters.
Secured Financing Adds Repayment And Covenant ExposureThe new facilities improve liquidity access but create durable obligations through interest costs, collateral security, maturities, and covenants. Because the company is already burning cash, weaker revenue execution could make compliance and future refinancing more consequential, limiting flexibility in capital allocation.
Shoulder Innovations, Inc. News
SI FAQ
What was Shoulder Innovations, Inc.’s price range in the past 12 months?
Shoulder Innovations, Inc. lowest stock price was $10.92 and its highest was $24.59 in the past 12 months.
What is Shoulder Innovations, Inc.’s market cap?
Shoulder Innovations, Inc.’s market cap is $393.48M.
When is Shoulder Innovations, Inc.’s upcoming earnings report date?
Shoulder Innovations, Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 46 days.
How were Shoulder Innovations, Inc.’s earnings last quarter?
Shoulder Innovations, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.459 by -$0.031.
Is Shoulder Innovations, Inc. overvalued?
According to Wall Street analysts Shoulder Innovations, Inc.’s price is currently Undervalued.
Does Shoulder Innovations, Inc. pay dividends?
Shoulder Innovations, Inc. does not currently pay dividends.
What is Shoulder Innovations, Inc.’s EPS estimate?
Shoulder Innovations, Inc.’s EPS estimate is -0.51.
How many shares outstanding does Shoulder Innovations, Inc. have?
Shoulder Innovations, Inc. has 20,818,956 shares outstanding.
What happened to Shoulder Innovations, Inc.’s price movement after its last earnings report?
Shoulder Innovations, Inc. reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.459. Following the earnings report the stock price went down -8.203%.
Which hedge fund is a major shareholder of Shoulder Innovations, Inc.?
Currently, no hedge funds are holding shares in SI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shoulder Innovations, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.33 (27.58% Upside)
$26.33 (27.58% Upside)
Blogger Sentiment
Bearish
SI Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 253.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
95.31%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Shoulder Innovations, Inc.
Shoulder Innovations, Inc. manufactures medical devices. It has developed a shoulder replacement system. The company was founded by Stephen B. Gunther and Michael DeVries in 2009 and is headquartered in Grand Rapids, MI.
SI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong operating and commercial momentum: sizable revenue and volume growth, improving gross margins, accelerating surgeon adoption and meaningful product and technology milestones (I-135 full launch, N22 limited release, >500 patients in registry, and a progressing robotic partnership). These positives were offset by increased operating expenses and larger net and adjusted EBITDA losses as the company invests to scale, a Q1 cash burn driven by inventory and working capital, and some seasonality and ASP/mix variability risk embedded in the updated guidance. Overall, management expressed high conviction in the trajectory and raised full-year guidance while noting near-term investment-related impacts.View all SI earnings summariesSI Stock 12 Month Forecast
Average Price Target
$26.33
▲(27.58% Upside)
Technical Analysis
Ownership Overview
28.25% Insiders
14.10% Mutual Funds
9.91% Other Institutional Investors
43.24% Public Companies and
Individual Investors